{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:03:25Z","timestamp":1794524605703,"version":"4.9.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the placebo response rate in PsA randomized clinical trials (RCTs), its contributing factors and impact on the effect size of active treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched multiple databases, from inception to 20 December 2020, for placebo-controlled RCTs in PsA. We used a random-effects meta-analysis to pool the response rates for the ACR20 criteria in the placebo arm, determined the risk difference for treatment vs placebo, and used meta-regression to determine the factors associated with placebo response rates. The risk of bias was assessed in duplicate. The study protocol was registered with PROSPERO: CRD42021226000.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 42 RCTs (5050 patients receiving placebo) published between 2000 and 2020. The risk of bias was low in 28 trials, high in four, and with some concerns in 10. The pooled placebo response rate was 20.3% (95% CI: 18.6%, 22.1%; predicted intervals, 11.7\u201329.0%), with significant between-trial heterogeneity (I2\u2009=\u200956.8%, P\u2009&amp;lt;\u20090.005). The pooled risk difference for treatment vs placebo was 27% (95% CI: 24%, 31%). In the multivariable meta-regression, there was a 15% (95% CI: 2.9%, 29.8%) increase in the odds of achieving the placebo response for each 5-year increment in publication year (P\u2009=\u20090.016). In addition, the active treatment risk difference decreased for every 5-year increment in publication year (\u03b2\u2009=\u2009\u22120.053, 95% CI: \u22120.099, \u22120.007; P\u2009=\u20090.024) but was not associated with the placebo response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite increasing over time, the placebo response for ACR20 in PsA RCTs was not associated with the active treatment effect size.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab774","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:34:12Z","timestamp":1634157252000},"page":"1328-1340","source":"Crossref","is-referenced-by-count":12,"title":["Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6818-7666","authenticated-orcid":false,"given":"Gian Luca","family":"Erre","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Universit\u00e0 degli Studi di Sassari"},{"name":"Dipartimento di Specialit\u00e0 Mediche, UOC Reumatologia, Azienda Ospedaliero-Universitaria, Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavridis","sequence":"additional","affiliation":[{"name":"Department of Primary Education, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard John","family":"Woodman","sequence":"additional","affiliation":[{"name":"Flinders Centre for Epidemiology and Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-1412","authenticated-orcid":false,"given":"Arduino Aleksander","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University"},{"name":"Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2022041112505205400_keab774-B1","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B2","first-page":"ii49","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00404165","article-title":"Drug effects and initial severity of symptomatology","volume":"7","author":"Fisher","year":"1965","journal-title":"Psychopharmacologia"},{"key":"2022041112505205400_keab774-B4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000490354","article-title":"Implications of placebo and nocebo effects for clinical practice: expert consensus","volume":"87","author":"Evers","year":"2018","journal-title":"Psychother Psychosom"},{"key":"2022041112505205400_keab774-B5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2022041112505205400_keab774-B6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc17-1316","article-title":"Magnitude and pattern of placebo response in clinical trials of oral antihyperglycemic agents: data from the Food and Drug Administration 1999\u20132015","volume":"41","author":"Khan","year":"2018","journal-title":"Diabetes Care"},{"key":"2022041112505205400_keab774-B7","doi-asserted-by":"crossref","first-page":"e2013196","DOI":"10.1001\/jamanetworkopen.2020.13196","article-title":"Assessment of placebo response in objective and subjective outcome measures in rheumatoid arthritis clinical trials","volume":"3","author":"Vollert","year":"2020","journal-title":"JAMA Netw open"},{"key":"2022041112505205400_keab774-B8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40261-020-00887-6","article-title":"Factors influencing placebo responses in rheumatoid arthritis clinical trials: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"40","author":"Nagai","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2022041112505205400_keab774-B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.190008","article-title":"Placebo response in rheumatoid arthritis clinical trials","volume":"47","author":"Bechman","year":"2020","journal-title":"J Rheumatol"},{"key":"2022041112505205400_keab774-B10","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2022041112505205400_keab774-B11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"issue":"3","key":"2022041112505205400_keab774-B12","first-page":"CD000212","article-title":"Interventions for treating psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2022041112505205400_keab774-B13","first-page":"CD012722","article-title":"Methotrexate for psoriatic arthritis","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022041112505205400_keab774-B14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2022041112505205400_keab774-B15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"2022041112505205400_keab774-B16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatology"},{"key":"2022041112505205400_keab774-B17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"2022041112505205400_keab774-B18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Statist"},{"key":"2022041112505205400_keab774-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"2022041112505205400_keab774-B20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"2022041112505205400_keab774-B21","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"2022041112505205400_keab774-B22","first-page":"15","article-title":"Assessing the influence of a single study in the meta-analysis estimate","volume":"8","author":"Tobias","year":"1999","journal-title":"Stata J"},{"key":"2022041112505205400_keab774-B23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"2022041112505205400_keab774-B24","author":"Erre"},{"key":"2022041112505205400_keab774-B25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022041112505205400_keab774-B31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B32","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022041112505205400_keab774-B34","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022041112505205400_keab774-B36","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B37","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B38","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022041112505205400_keab774-B39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B40","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B41","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2022041112505205400_keab774-B42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022041112505205400_keab774-B43","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor\u2013 and interleukin-17a\u2013targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022041112505205400_keab774-B44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B45","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"key":"2022041112505205400_keab774-B46","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022041112505205400_keab774-B47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2022041112505205400_keab774-B48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B49","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B50","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"2022041112505205400_keab774-B51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B52","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"2022041112505205400_keab774-B54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B55","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B56","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B58","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2022041112505205400_keab774-B59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"2022041112505205400_keab774-B60","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B61","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B62","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B63","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022041112505205400_keab774-B64","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022041112505205400_keab774-B65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab774\/41099013\/keab774.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1328\/43356136\/keab774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1328\/43356136\/keab774.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:57:25Z","timestamp":1649681845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/4\/1328\/6402020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2022,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab774","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,10,19]]}}}